Osimertinib Mesylate from Japan
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Duty Rate — Japan → United States
12.5%
Rate breakdown
9903.05.4912.5%Section 301 (forced labor) — Japan (col1 rate < 12.5 percent): MFN < 12.5% → total duty capped at 12.5%
Import Tips
• Include polymorphic form designation (Form A) in import documentation
• Particle size distribution critical for bioavailability - include laser diffraction data
• Declare therapeutic class on entry summary to facilitate FDA review